VP research
SpliSense Ltd., Jerusalem, Israel, Israel
Efrat Ozeri- Galai, PhD, co-founder and VP Research of SpilSense, a biotech company developing innovative RNA therapies, based on Antisense Oligonucleotides (ASOs), addressing untreatable genetic illnesses and pulmonary diseases. The first projects of Splisense are concentrating on providing treatment for specific CF patient populations with unmet need which are not trageted or are low responsive to the available CF modulators. Since company establishment I have been leading the research team at Splisense and overseeing early discovery, screening for lead drug candidates and preclinical pharmacology. My background is in human genetics specifically in pulmonary diseases and RNA modulation as well as genetic instability.